Scotiabank Initiates Coverage On Keros Therapeutics with Sector Outperform Rating, Announces Price Target of $77

Benzinga · 10/16 14:36
Scotiabank analyst Greg Harrison initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Sector Outperform rating and announces Price Target of $77.